ARBITER-6 HALTS - Should Niacin Be The Preferred Add-On Therapy?

Print
Moderator: 
Zachariah Deyo, Pharm.D.
Panelists: 
Michael Miller, MD
David Roffman, Pharm.D.
Reviewed By: 
Kathryn Kiser, Pharm.D., BCPS
Stuart T. Haines, Pharm.D., BCPS, BC-ADM
Citation: 
Extended-Release Niacin or Ezetimide and Carotid Artery Intima-Media Thickness. NEJM 2009; 361: 2113-22

The ARBITER-6 HALTS study examined the benefits of statin add-on therapy with either ezetimibe or niacin. Although not intended to be an outcome study, a significant difference between exetimibe and niacin in terms of cardiovascular events was observed in this study. How much weight should we give to this surprising finding?

Get Adobe Flash player